Celgene Corporation (NASDAQ:CELG) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $98.99 with a loss of -1.24 points or -1.24%. The net money flow was $71.4 million and the up/down ratio was 2.29. Approximately $126.54 million was the inflow in upticks and $55.15 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -3.81%.The shares witnessed a block transaction with a net money flow of $70.72 million. The total money in uptick was $73.5 million and in downtick was $2.78 million with the up/down ratio reaching 26.41.
Celgene Corporation has lost 4.05% in the last five trading days and dropped 2.32% in the last 4 weeks. Celgene Corporation has dropped 0.02% during the last 3-month period . Year-to-Date the stock performance stands at -17.55%.
Currently the company Insiders own 0.96% of Celgene Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.05% . Institutional Investors own 81.31% of Celgene Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -24.94%. . On the companys insider trading activities, The Securities and Exchange Commission has divulged that Kaplan Gilla, director of Celgene Corp /De/, had unloaded 15,967 shares at an average price of $101.84 in a transaction dated on April 4, 2016. The total value of the transaction was worth $1,626,079.
Celgene Corporation (NASDAQ:CELG) witnessed a decline in the market cap on Friday as its shares dropped 1.49% or 1.49 points. After the session commenced at $100.43, the stock reached the higher end at $100.43 while it hit a low of $98.22. With the volume soaring to 5,976,683 shares, the last trade was called at $98.74. The company has a 52-week high of $140.72. The company has a market cap of $76,484 million and there are 774,601,500 shares in outstanding. The 52-week low of the share price is $92.98.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.